PABPC4

Across TCGA pan-cancer cohorts, PABPC4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PABPC4 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PABPC4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PABPC4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where PABPC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.306	0.760	.002	61	view →
LUAD	OS	Quartile	II,III,IV	0.927	0.516	.012	21	view →
HNSC	DFS	Median	II,III,IV	0.900	0.970	.026	6	view →
PDAC	OS	Median	II,III,IV	0.906	0.807	.027	2	view →
LSCC	DFS	Median	All	0.956	0.920	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PABPC4–CCRCC (DFS)

Open the CCRCC breakdown →